Introduction
============

The heart relies on a complex network of cells to maintain appropriate function. Cardiomyocytes, the contracting cells in the heart, exist in a three-dimensional network of endothelial cells, vascular smooth muscle, and an abundance of fibroblasts as well as transient populations of immune cells. Gap junctions electrochemically coordinate the contraction of individual cardiomyocytes, and their connection to the extracellular matrix (ECM) transduces force and coordinates the overall contraction of the heart. Intracellularly, repeating units of actin and myosin form the backbone of sarcomere structure, the basic functional unit of the cardiomyocyte ([Fig. 1](#fig1){ref-type="fig"}). The sarcomere itself consists of ∼20 proteins; however, more than 20 other proteins form connections between the myocytes and the ECM and regulate muscle contraction ([Fig. 1 B](#fig1){ref-type="fig"}). Given the complexity of the coordinated efforts of the many proteins that exist in multimeric complexes, dysfunction occurs when these interactions are disrupted.

![**Anatomy of the cardiac sarcomere.** (A) Diagram of the basic organization of the sarcomere. The sarcomere forms the basic contractile unit in the cardiomyocytes of the heart. Thin filaments composed of actin are anchored at the Z line and form transient sliding interactions with thick filaments composed of myosin molecules. The M Line, I Band, and A Band are anatomical features defined by their components (actin, myosin, and cytoskeletal proteins) and appearance in polarized light. Titin connects the Z line with the M line and contributes to the elastic properties and force production of the sarcomere through its extensible region in the I Band. Coordinated shortening of the sarcomere creates contraction of the cardiomyocyte. (B) Representation of the major proteins of the cardiac sarcomere. Attachment to the ECM is mediated by costameres composed of the dystroglycan--glycoprotein complex and the integrin complex. Force transduction and intracellular signaling are coordinated through the costamere. The unique roles of each of these proteins are critical to appropriate function of the heart. T-cap, titin cap; MyBP-C, myosin-binding protein C; NOS, nitric oxide synthase.](JCB_201101100_RGB_Fig1){#fig1}

Although the heart may functionally tolerate a variety of pathological insults, adaptive responses that aim to maintain function eventually fail, resulting in a wide range of functional deficits or cardiomyopathy. Although a multitude of intrinsic and extrinsic stimuli promote cardiomyopathies, the best described causes are the \>900 mutations in genes expressed in the cardiomyocyte ([Fig. 1 B](#fig1){ref-type="fig"}; [@bib103]). Mutations in most of these genes cause a diverse range of cardiomyopathies, many with overlapping clinical phenotypes. Mutations in sarcomeric genes are usually inherited in an autosomal-dominant manner and are missense mutations that are incorporated into sarcomeres ([@bib90]). Thus far \>400 mutations in 13 sarcomeric proteins including β-myosin heavy chain (β-MyHC), α-cardiac actin, tropomyosin, and troponin have been associated with cardiomyopathy ([www.cardiogenomics.med.harvard.edu](www.cardiogenomics.med.harvard.edu)). [Table I](#tbl1){ref-type="table"} summarizes these mutated proteins.

###### 

Cardiomyopathies, genetic causes, and cellular pathology

  Disease                                           Mutated gene                       Pathology
  ------------------------------------------------- ---------------------------------- ----------------------------------------------
  Hypertrophic cardiomyopathy                       Myosin binding protein C           Increased heart mass
                                                    **β-Myosin heavy chain**           Left ventricular wall thickening
                                                    α-Myosin heavy chain               Increased cardiomyocyte size
                                                    **α-Tropomyosin**                  Myofibrillar disarray
                                                    **Troponin T**                     Decreased volume of left ventricular chamber
                                                    **α-Cardiac actin**                Interstitial fibrosis
                                                    **Troponin I**                     Enlarged nuclei
                                                    **Titin**                          Ventricular wall stiffness
                                                    Myosin light chains                Inflammation
                                                    **Troponin C**                     
                                                    **Vinculin**                       
                                                    Muscle LIM protein                 
                                                    Telothonin                         
  Dilated cardiomyopathy                            **β-Myosin heavy chain**           Ventricular wall thinning
                                                    **Desmin**                         Ventricular chamber enlargement
                                                    N-cadherin                         Cardiomyocyte apoptosis
                                                    **α-Cardiac actin**                Interstitial fibrosis
                                                    Skeletal muscle myopathies         Enlarged nuclei
                                                    **α-Tropomyosin 1**                Ventricular wall stiffness
                                                    Muscle LIM protein δ-sarcoglycan   Inflammation
                                                    Lamin A/C                          
                                                    **TAZ (G4.5)**                     
                                                    **Titin**                          
                                                    Phospholamban                      
                                                    **Vinculin**                       
                                                    **Troponin I**                     
                                                    **Troponin T2**                    
                                                    SCN5A                              
                                                    Presenilin 1 & 2                   
                                                    **Troponin C**                     
                                                    **α-Cardiac actinin**              
                                                    Plakoglobin                        
  Restrictive cardiomyopathy                        **Troponin I**                     Ventricular wall stiffness
                                                    **Desmin**                         Apoptosis
                                                    **α-Cardiac actin**                Fibrosis
                                                    Skeletal muscle myopathies         Myofibrillar disarray
                                                    Troponin T                         
                                                    **β-Myosin heavy chain**           
  Left ventricular noncompaction                    **TAZ (G4.5)**                     Trabeculated ventricular walls
                                                    α-Dystrobrevin                     Noncompaction of ventricular endocardium
                                                    FKBP12                             Necrotic myocytes
                                                    **β-Myosin heavy chain**           Fibrosis
                                                    **α-Cardiac actin**                Myofibrillar disarray
                                                    **Cardiac troponin**               
  Arrhythmogenic right ventricular cardiomyopathy   Plakophilin-2                      Right ventricular dilation
                                                    Junctional plakoglobin             Right ventricular fibrosis
                                                    Desmocollin-2                      Fibrofatty infiltration
                                                    Desmoglein-2                       Apoptosis
                                                    Desmoplakin                        
  Muscular dystrophy--associated cardiomyopathy     Dystrophin                         Left ventricular hypertrophy or dilation
                                                    Sarcoglycan                        Fibrosis
                                                    Dystroglycan                       Apoptosis
                                                    Dystrobrevin                       

Bold: mutations that are common to multiple forms of cardiomyopathy.

There are several examples in which mutations in the same gene can cause different disease phenotypes (indicated in bold in [Table I](#tbl1){ref-type="table"}), suggesting that the position of the mutation within the gene influences the cardiac phenotype. Clinical phenotypes are also likely to be modified by sex hormones, diet, and polymorphisms in many genes including those involved in angiotensin signaling, thus complicating attempts to make predictive correlations between specific mutations with disease prognosis ([@bib59]; [@bib16]; [@bib98]). In fact, a modifier gene was identified in one strain of mice that blocked the pathology induced by a mutated β-MyHC (R403Q) in another strain of mice ([@bib91]). Characterization and mechanistic study of cardiomyopathies are therefore challenging owing to the complex protein structures, the multitude of disease-causing mutations, and modulators of pathology.

A wide range of inherited and acquired cardiomyopathies has been described by the World Health Organization: hypertrophic cardiomyopathy, dilated cardiomyopathy, restrictive cardiomyopathy, and arrhythmogenic right ventricular cardiomyopathy as well as a large group of unclassified cardiomyopathies. Acquired cardiomyopathies induced by stress, diabetes, some chemotherapeutic agents, pregnancy, and alcohol intake, for example, represent a diverse class of cardiac disease ([@bib7]; [@bib81]; [@bib18]; [@bib17]; [@bib36]). In this review, we focus on inherited cardiomyopathies with known mutations in proteins expressed in the heart, describing their prevalence, pathology, and the cellular mechanisms of disease.

Inherited cardiomyopathies
==========================

Hypertrophic cardiomyopathy (HCM).
----------------------------------

HCM, which is inherited in an autosomal-dominant pattern in more than 50% of patients, occurs in ∼1 in 500 individuals with men affected nearly twice as much as women and is the leading cause of sudden cardiac death among young people in North America ([@bib58], [@bib59]; [@bib57]).

Mutations in 13 sarcomeric proteins have been associated with HCM; those in β-MyHC were the first to be identified in HCM and cause 30% of all cases ([@bib40]; [@bib79]). Clinical phenotypes associated with these mutations range from mild to severe, likely due to the locations of mutations in different functional domains as well as genetic modifiers and environmental stimuli. Most mutations are in the motor domain of myosin; however, disease-causing mutations in the rod region have also been identified ([@bib6]). It is not yet clear whether clinical predictions can be made based solely on which functional domains carry mutations.

Cardiac dysfunction in HCM is attributable to initial increases in heart mass and asymmetric interventricular septal thickening ([Fig. 2, A and B](#fig2){ref-type="fig"}; [@bib59]; [@bib56]; [@bib103]). Histological hallmarks include an increase in cardiomyocyte size, disorganized arrangement of myocytes (myofibrillar disarray), and both perivascular and interstitial fibrosis, a common phenotype in many cardiomyopathies. Persistent cardiac architectural changes in HCM can result in thinning of the ventricular walls, dilation of the ventricular chamber, and decreases in cardiac output that can lead to heart failure.

![**Gross pathology associated with cardiomyopathies.** Illustrations depicting (A) a healthy heart with normal wall thicknesses and chamber volumes and (B) hypertrophic cardiomyopathy. Asymmetric hypertrophy of the interventricular septum as well as the left ventricular posterior wall and apex is present. (C) Dilated cardiomyopathy. Thinning of the ventricular walls enlarges the interior dimensions of the ventricular chamber. The left and right atria are also enlarged due to impaired ventricular relaxation. (D) Left ventricular noncompaction. Trabeculated ventricular walls create a spongy appearance, prominent in the left ventricular wall. Ao, aorta; LA, left atrium; LV, left ventricle; RV, right ventricle.](JCB_201101100_RGB_Fig2){#fig2}

Dilated cardiomyopathy (DCM).
-----------------------------

DCM occurs in 1 in 2,500 individuals in the United States and is considered the most prevalent form of cardiomyopathy because it is a common clinical outcome of many prolonged cardiac insults ([@bib11]; [@bib102]). Enlargement of the ventricular chamber and thinning of the ventricular walls are the predominant phenotypes in this disease ([Fig. 2 C](#fig2){ref-type="fig"}). Loss of heart mass is highly correlated with heart failure and mortality; indeed, 50% of those diagnosed with DCM die within five years of becoming symptomatic ([@bib64]; [@bib27]).

Although DCM can occur secondary to systemic pathology, approximately one half of cases are not associated with a systemic cause (idiopathic DCM). Among these cases, about one third of patients have a family history of DCM (familial DCM) that is transmitted autosomally (recessive and dominant), through maternal mitochondrial DNA, or as an X-linked mutation ([@bib5]; [@bib45]; [@bib62]). In contrast to HCM, which is almost exclusively associated with mutations in sarcomeric proteins, familial DCM is primarily associated with mutations in cytoskeletal proteins ([Table I](#tbl1){ref-type="table"}). These and other proteins that connect the sarcomere to the ECM form the mechanotransduction apparatus that allows cardiomyocytes to sense and respond to changes in contractility. Disruption of components of this apparatus therefore prevents the heart from productively responding to both extrinsic and intrinsic stressors.

Restrictive cardiomyopathy (RCM).
---------------------------------

RCM is the least common but most lethal form of cardiomyopathy ([@bib14]). Causes of RCM are extremely variable and include induced and genetic initiators as well as idiopathic etiologies. Idiopathic RCM occurs in the absence of other pathology, although it can be associated with skeletal muscle myopathies ([@bib44]). Injury to the heart caused by radiation, scarring after heart surgery, infection, or diseases such as amyloidosis can also cause RCM. Recently, mutations in the sarcomeric protein troponin I, which participates in the regulation of calcium-mediated actin--myosin interactions and contractility, were associated with a familial form of the disease, and it is now recognized as the primary disease-causing mutation in familial RCM ([@bib67]). Mutations in other sarcomeric proteins such as cardiac desmin, α-cardiac actin, and β-MyHC as well as mutations that have been implicated in HCM have been described in RCM patients ([@bib43]; [@bib78]).

Unlike in HCM, alterations in tissue flexibility occur in RCM in the absence of changes in ventricular myofibrillar arrangement and gross abnormalities ([@bib34]). RCM is, therefore, characterized by increased stiffness of the myocardium that causes increased pressure in one or both ventricles. Ventricular relaxation is impaired, similar to the phenotype observed in HCM, and the atria then enlarge in response to the increased pressure in some patients ([@bib78]). The restrictive phenotype is common to RCM and some cases of HCM, emphasizing the need for more precise diagnostic criteria.

Arrhythmogenic right ventricular cardiomyopathy (ARVC).
-------------------------------------------------------

ARVC occurs in ∼1 in 5,000 individuals and primarily affects adults ([@bib4]). However, ARVC is also an important cause of death among young people, accounting for ∼20% of deaths occurring in individuals under 30 years old ([@bib92]). ARVC is inherited in an autosomal-dominant or recessive pattern in 50% of cases often with incomplete penetrance, so unknown genetic or environmental modifiers are predicted ([@bib4]).

Mutations in proteins that comprise the cardiac desmosome, a junctional complex that mechanically couples neighboring cardiomyocytes to coordinate contractile activity, account for most inherited cases of ARVC ([@bib106]). Disruptions in desmosome stability cause structural and functional alterations and are associated with cardiomyocyte apoptosis ([@bib105]). Adipose and fibrotic tissue that replace cardiomyocytes are a hallmark of ARVC, primarily in the right ventricle; however, left ventricular involvement is common in later stages of the disease ([@bib10]). The right ventricle enlarges as myocyte loss progresses, causing a reduction in blood volume pumped from the heart and arrhythmias.

Left ventricular noncompaction cardiomyopathy (LVNC).
-----------------------------------------------------

LVNC, a recently delineated form of cardiomyopathy, is defined anatomically by deep trabeculations that create a spongiform appearance of the ventricular walls ([Fig. 2 D](#fig2){ref-type="fig"}; [@bib8]). Clinically, patients present with depressed systolic and diastolic dysfunction, left and right ventricular hypertrophy, arrhythmias, and, in some cases, conduction block. Familial forms with autosomal-dominant or X-linked transmission account for up to 50% of all LVNC cases ([@bib8]; [@bib87]). The mechanisms responsible for pathology are poorly defined, but indirect evidence suggests that malformation of the myocardium contributes to functional abnormalities in the adult ([@bib107]). During development, the loose network of fibers that form the myocardium becomes compacted between the fifth and eighth prenatal weeks. In patients with LVNC, a normal pattern of compaction occurs in the outer band of the myocardium, but an abnormal noncompacted region within the inner (endocardial) layer localized mainly in the apical and midventricular regions of the heart is also observed ([Fig. 2 D](#fig2){ref-type="fig"}; [@bib8]; [@bib80]; [@bib23]) . Similarities among LVNC, HCM, and DCM, likely caused by mutations in the same gene (β-MyHC, for example), motivate differential diagnosis criteria aimed at better defining this syndrome ([@bib104]; [@bib41]).

Cardiomyopathies associated with muscular dystrophies.
------------------------------------------------------

Muscular dystrophies, caused by autosomal-recessive mutations in proteins that anchor the sarcomere to the ECM, are a heterogeneous group of skeletal muscle disorders. Incidence of cardiac involvement among patients with muscular dystrophies varies and is dependent upon the disease-causing mutations. Although Duchenne and Becker muscular dystrophies are X-linked, up to 18% of female carriers that do not exhibit skeletal muscle disease exhibit heart failure, illustrating that even subtle disruption of the interactions between the sarcomere and ECM can impart cardiac dysfunction ([@bib33]).

Identification of disease-causing mutations in the heart has contributed to the delineation of many phenotypically similar cardiomyopathies. However, much work remains in elucidating the specific cellular mechanisms of disease. In the past decade, resources available to study cardiomyopathies at the cellular level have evolved to allow the study of mechanisms of pathogenesis using a variety of experimental approaches including in vitro biochemistry, cell biology, and animal models ([@bib21]; [@bib29]; [@bib55]). These studies have revealed the roles of a variety of cell types in the development of cardiomyopathy. In addition to cardiomyocyte-mediated effects, nonmyocytes induce functional changes in cardiomyocytes and in the structural properties of the ECM. Deposition of collagen by fibroblasts, for example, creates fibrotic scars that stiffen the heart tissue and impede normal cardiomyocyte contractility. In the sections that follow, we present an overview of the cellular pathology mediated by cardiac cells with an emphasis on the cardiomyocyte, whose responses to intrinsic and extrinsic insults most profoundly affect cardiac function.

Altered cardiomyocyte cell biology in cardiomyopathy
====================================================

Different classifications of cardiomyopathy exhibit a subset of overlapping symptoms, emphasizing the limited range of cellular responses in the cardiomyocyte ([Table I](#tbl1){ref-type="table"}). Alterations in gene expression patterns, changes in cellular morphology, and metabolic shifts in cardiomyocytes initially improve or maintain function in the early stages of many forms of cardiomyopathy. An exception to this is DCM, which does not appear to progress through this initial series of compensatory responses. Patients with DCM exhibit a dilated phenotype that decompensates rapidly when patients become symptomatic, similar to end-stage heart failure HCM.

Cardiomyocyte hypertrophy.
--------------------------

In response to altered contractility or physiological stress, ventricular cardiomyocytes increase in size to keep pace with increased functional demand, thus increasing the thickness of the walls but reducing interior dimensions of the ventricular chambers. Regardless of the initial stimulus, cardiac hypertrophy is thought to be compensatory as it normalizes increased stress in the ventricular wall and augments the contractile capacity of the heart. The development of hypertrophy therefore implies an anatomical adaptation that does not explicitly signify a disease state.

Cardiac hypertrophy is attributable to structural alterations within individual cardiomyocytes. The addition of sarcomeres in parallel is an adaptive response to increase force production in stressed cells. Increased myocyte width (concentric hypertrophy; [Fig. 3, A and B](#fig3){ref-type="fig"}) correlates with compensatory ventricular hypertrophy, a hallmark of HCM. In HCM, however, concentric hypertrophy causes a distortion of the cardiomyocyte alignment, which may affect contractility in the heart ([@bib90]). There remains no clear consensus on whether cardiomyocyte hypertrophy is truly compensatory or merely a component in the pathway to heart failure. However, when hypertrophic growth in a myosin model of HCM was blocked by constitutive activation of glycogen synthase kinase 3β (GSK3β), all male animals died, suggesting that the initial phases of hypertrophy are indeed compensatory ([@bib54]). Persistent hypertrophy with disease is positively associated with the development of heart failure. After an initial phase of compensatory hypertrophy, addition of sarcomeres to ventricular cardiomyocytes increases length-to-width ratios, which leads to decreased force production. Increased myocyte length produced by end-to-end addition of sarcomeres (eccentric hypertrophy; [Fig. 3, C and D](#fig3){ref-type="fig"}) is associated with ventricular dilation in DCM and with advanced HCM.

![**Isolated cardiomyocytes exhibiting hypertrophy and heart failure.** (A) Untreated adult ventricular cardiomyocyte demonstrating normal brick-like morphology. (B) An adult ventricular cardiomyocyte treated with endothelin-1 precursor protein exhibiting significant concentric hypertrophy. The cardiomyocyte is decreased in length and increased in width, consistent with the phenotype observed in human cardiomyocytes with concentric hypertrophy. A and B are reproduced from [@bib28] with permission from Elsevier. (C) Cardiomyocyte isolated from a healthy human heart. (D) Cardiomyocyte isolated from the heart of a patient in heart failure. Increased length and decreased width are characteristic of eccentric hypertrophy. C and D are reproduced from [@bib75] with permission from Brian O'Rourke.](JCB_201101100_GS_Fig3){#fig3}

Fetal gene program.
-------------------

In cardiomyopathy, induction of genes normally expressed during embryogenesis occurs including natriuretic factors, β-MyHC, and α-skeletal actin ([@bib50]). Natriuretic proteins secreted by cells in the atria and ventricles, atrial natriuretic factor (ANF) and brain natriuretic peptide (BNP), respectively, induce diuresis and vasodilation, which are capable of reducing blood volume and pressure in response to increased wall stress. These factors are up-regulated in response to transient increases in blood pressure. However, in cardiomyopathy, transcription and secretion are chronic.

ANF expression is increased in atrial myocytes when hearts exhibit diastolic dysfunction, which increases tension on the walls of the atria, and is released by ventricular myocytes when there is increased pressure on the ventricular walls in cardiomyopathy ([@bib82]; [@bib19]). Ventricular hypertrophy causes excessive stress in the ventricular wall during contraction, which also serves as a stimulus for release of BNP ([@bib46]). Induced expression of these genes, therefore, implies a cardioprotective mechanism that indirectly attempts to normalize pathological changes that affect the heart. Some evidence suggests that these genes may be anti-hypertrophic to prevent overgrowth of the organ in response to stress ([@bib94]).

Myosin isoform shift.
---------------------

In the face of a wide variety of pathological insults, up-regulation of the β-MyHC isoform occurs. Myosin exists as two heavy chains and two pairs of light chains. Cardiac muscle contains two isoforms of MyHC, α-MyHC and β-MyHC, which are expressed in species-specific proportions in the heart. β-MyHC accounts for more than 90% of the MyHC in the adult human ventricle. The proportion of these isoforms in the heart is tightly regulated, such that up-regulation of β-MyHC expression with a concomitant decrease in α-MyHC in the hearts of humans and rodents is a sensitive marker of early cardiomyopathy ([@bib53]; [@bib66]). This response may be adaptive, as β-MyHC exhibits lower ATPase activity resulting in improved ATP use, and may be a requirement in the presence of mutations that reduce efficiency of contractility. However, features of β-MyHC, which exhibits slower filament sliding velocity, may contribute to pathology ([@bib89]).

Contractility of the heart is inversely proportional to the amount of expression of β-MyHC ([@bib77]; [@bib31]). Titration of β-MyHC expression in adult ventricular cardiomyocytes results in a dose-dependent reduction in sarcomere shortening and velocity, independent of Ca^2+^ handling ([@bib32]). The shift toward β-MyHC in the pathological heart may contribute to the decreased myocyte shortening and prolonged relaxation of cardiomyocytes observed during the transition from compensatory hypertrophy to heart failure ([@bib70]).

Fibrosis.
---------

The development of interstitial and perivascular fibrosis is a hallmark of pathology in the heart. Focal fibrosis, composed primarily of collagen types I and III, occurs in the early stages of cardiomyopathy, but over time fibrosis increases and directly compromises the function of cardiomyocytes. The presence of collagen-rich regions in the myocardium causes disruption of excitation--contraction coupling between cardiomyocytes and increased stiffness of the myocardium, and leads to decreased contractility in the heart ([@bib61]). Fibrosis is primarily produced by resident fibroblasts in the heart; however, there is evidence for collagen production by cardiomyocytes ([@bib88]).

Recent studies support a link between sarcomere mutations and gene expression changes in nonmyocytes that promotes production of fibrosis. Increased transcription and release of TGF-β in the hearts of mice expressing HCM-causing mutations in α-MyHC (R403Q, R719W) activate nonmyocytes and promote increased focal and interstitial fibrosis ([@bib100]). Interference with the development of excessive fibrosis in the hearts of patients with cardiomyopathy could represent a promising therapy to reduce the functional deficits that result from disease-causing mutations in cardiomyocytes.

Alteration in metabolic substrate utilization.
----------------------------------------------

In the healthy heart, phosphocreatine is the main reserve source of ATP during acute stress. As pathogenesis progresses in cardiomyopathy, the demand for ATP increases, and the levels of phosphocreatine are progressively depleted ([@bib37]; [@bib96]). This reduction in energy-rich resources forces the heart to favor alternative energy substrates during prolonged stress mediated by exogenous cardiotoxic stimuli or contractile dysfunction caused by mutated sarcomeric proteins. During the initial compensatory stages of cardiomyopathy, substrate utilization favors free fatty acids, which yield about three times more ATP than glucose but require more oxygen to metabolize, making it a more lucrative but less efficient means to produce energy ([@bib3]; [@bib73]).

In the failing heart, as in DCM and end-stage HCM, energy substrate utilization in the heart shifts from fatty acid oxidation to glucose utilization, a less efficient means of producing energy ([@bib97]; [@bib39]; [@bib13]). A proposed mechanism for this transition from compensatory to decompensatory cardiac hypertrophy is excessive cardiac growth without adequate coronary angiogenesis. A mildly hypoxic state up-regulates genes that facilitate utilization of glucose instead of fatty acids ([@bib35]). This is supported by studies in the developing heart in which exposure to the oxygen-rich postnatal environment at birth correlates with a dramatic shift in metabolic enzyme isoforms to use fatty acids as an energy substrate ([@bib52]). Indeed, hypertrophy induced by volume overload in newborns delays this shift ([@bib42]). Expression and activity of enzymes that mediate fatty acid use, such as medium-chain acyl-CoA dehydrogenase and peroxisome proliferator-activated receptor-α, are down-regulated in the failing adult heart to resemble expression in the fetal heart ([@bib84]). Therefore, the heart progresses through several stages of metabolic changes as it enters heart failure: the increased use of fatty acids during compensation and a shift to glucose utilization as the heart decompensates.

Sensing and responding to cellular stress
=========================================

The cellular responses observed in cardiomyopathies arise from the detection of functional changes mediated primarily by ECM--sarcomere connections and collectively aim to maintain sufficient contractile force and prevent progression to heart failure. Signaling pathways initiated by mechanotransduction in the cardiomyocyte initially serve to reduce blood volume, add sarcomeres to increase contractile capacity, and shift metabolic processes to those that favor the utilization of substrates that yield more energy (lipids).

Mechanotransduction and signaling in the cardiomyocyte.
-------------------------------------------------------

The responses of cardiomyocytes to systemic stress or genetic abnormalities are modulated by mechanosensitive mechanisms within the cardiomyocyte ([@bib68]; [@bib90]; [@bib24]). A complex network of proteins that connects the sarcomere to the ECM forms the basis of the mechanotransduction apparatus. For example, components of the costamere complex, which form the connection between the sarcomere and the ECM via integrins, initiate intracellular signaling and subsequently alter contractile properties and transcriptional regulation in response to membrane distortion. Mechanosensitive ion channels are also implicated in signal initiation in response to systemic stress ([@bib51]; [@bib108]; [@bib15]). These channels are likely responsible for acute changes that might initiate other longer-term responses in the heart but are nonetheless important to consider when examining possible transducers of systemic and tissue alterations to the cardiomyocyte.

Changes in wall stress induce signaling pathways that are associated with the development of cardiac pathology. The many intracellular signaling pathways that mediate responses to increased demand on the heart have been extensively reviewed elsewhere ([@bib22]; [@bib68]; [@bib30]). Here, we focus on pathways that are intimately involved in pathogenesis ([Fig. 4](#fig4){ref-type="fig"}). Although their effects in compensatory responses early in pathology initially increase function by promoting growth and contractility, persistent responses eventually compromise function.

![**Signaling pathways associated with cardiac hypertrophy.** Although many pathways are associated with cardiomyopathy, up-regulation of transcription and induction of apoptosis are major mediators of pathogenic responses in the heart. The GPCR-associated pathway (dark red) can be activated by ET-1 and AngII, which are released in response to reduced contractility, and mediates contractile adaptation through increased calcium release from the sarcoplasmic reticulum. Increased intracellular calcium activates calmodulin and induces activation of the transcription factor MEF2. Incorporation into the sarcomere of mutant proteins that exhibit reduced ATP efficiency inhibits the sequestration of calcium from the cytosol and further enhances increases in intracellular calcium concentration. GPCR signaling is also associated with activation of the Akt signaling pathway (light green) that induces fetal gene expression and the cardiac hypertrophic response through inhibition of GSK3β. Apoptotic pathways (light blue) are induced by cytochrome *c* (CytC) release from mitochondria and activation of death receptors (like FasR) by cytokines such as TNF. Calcium overload and myocyte loss significantly contribute to reduced contractility in many forms of cardiomyopathy. ET-1, endothelin-1; HDAC, histone deacetylase; NFAT, nuclear factor of activated T cells; MEF-2, myocyte enhancer factor 2; SERCA, sarco/endoplasmic reticulum calcium-ATPase; cFLIP, cellular FLICE-inhibitory protein; AngII, angiotensin II; FasR, Fas receptor.](JCB_201101100_RGB_Fig4){#fig4}

Akt signaling.
--------------

Akt, the major effector of phosphoinositide 3-kinase (PI3K) signaling, mediates many processes important to cardiac adaptation including protein synthesis, inhibition of apoptosis, and metabolism. Despite clear beneficial effects of acute Akt activation, chronic activation of the PI3K/Akt pathway causes cardiomyopathy. The divergent effects of activated Akt are dependent on the length of time Akt is activated and the initiator of the pathway. Mice expressing constitutively activated (myristoylated) Akt have hearts and cardiac myocytes that are approximately twofold larger than littermate controls and are protected from ischemia reperfusion injury. However, other founder mice expressing the transgene die with cardiac enlargement and presumed heart failure ([@bib60]). Also, a conditional mutant with activated Akt1 exhibits reversible hypertrophy with two weeks of transgene expression but irreversible hypertrophy with fibrosis and reduced angiogenesis when expressed for six weeks ([@bib93]). Therefore, activation of Akt signaling increases cell size and contractile efficiency in the face of acute intensification of functional demand; however, the temporal activation of this pathway determines whether the adaptive effects are maintained productively ([@bib60]; [@bib74]).

Downstream of Akt is the kinase GSK-3β, which negatively regulates cardiomyocyte size. GSK-3β is largely unphosphorylated and constitutively active in the healthy heart; phosphorylation of GSK-3β by Akt inactivates it. Overexpression of activated GSK-3β causes reduced heart size and decreased hypertrophy in response to pathological stimuli ([@bib29]; [@bib63]). In genetic models of HCM with mutations in sarcomeric proteins, GSK-3β is inactivated, consistent with hypertrophy in these models and demonstrating downstream alterations in the Akt signaling cascade ([@bib98]; [@bib54]).

G protein signaling.
--------------------

Pathological stimuli that induce increased pressure or mechanical stretch in the heart promote release of several paracrine and autocrine factors including adrenergic factors, angiotensin II, and endothelin (ET1), which each activate G protein--coupled receptor (GPCR) signaling. G protein subunits serve as effectors for downstream signaling cascades and modulate cardiac adaptation, namely those processes intended to increase force production like cardiomyocyte hypertrophy. Mechanical stretch of adult ventricular cardiomyocytes and administration of Gα~q~ activating agents (norepinephrine, angiotensin II) in neonatal rat ventricular myocytes specifically induce hypertrophy ([@bib85]; [@bib48]). Each of the agents that activate Gα~q~ in neonatal rat ventricular myocytes also induces activation of phospholipase C and hypertrophy ([@bib95]; [@bib47]; [@bib1]; [@bib86]). In agreement with these data, Gα~q~ attenuation decreases hypertrophy, cardiac remodeling, and functional deficits in response to pressure overload in mice ([@bib20]). Transgenic mice overexpressing Gα~q~ exhibit cardiac growth similar to that induced by pressure overload, independent of this stimulus ([@bib12]; [@bib86]). The hearts of these mice also exhibit some qualities of pathological hypertrophy including left ventricular dysfunction and induction of the fetal gene program indicative of cardiomyopathy ([@bib12]; [@bib86]).

Ca^2+^ regulation and calcineurin signaling.
--------------------------------------------

Ca^2+^ concentrations inside the cardiomyocyte are critically important to actin--myosin interactions. Ca^2+^ is sequestered within the sarcoplasmic reticulum and the sarcomere itself, which serves as an intracellular reserve that is released in response to electrical stimulation of the cardiomyocyte. After contraction, sarco/endoplasmic reticulum Ca^2+^-ATPase sequesters the Ca^2+^ back into the sarcoplasmic reticulum to restore Ca^2+^ balance. There is a clear correlation between force production and perturbation of Ca^2+^ regulation, alterations of which might directly induce pathological, anatomical, and functional alterations that lead to heart failure via activation of GPCRs ([@bib65]).

Ca^2+^ in the cytosol can be increased to modulate sarcomere contractility by signaling through Gα~q~ recruitment and activation of PLCβ. Ca^2+^ released from the sarcoplasmic reticulum activates calmodulin, which phosphorylates calcineurin, a serine/threonine phosphatase. Upon activation, calcineurin interacts with and dephosphorylates nuclear factor of activated T cells (NFAT), which then translocates into the nucleus. Calcineurin activation exacerbates hypertrophic signals and expedites the transition to a decompensatory state. Indeed, cardiac-specific overexpression of calcineurin or NFAT leads to significant cardiac hypertrophy that progresses rapidly to heart failure ([@bib69]). Administration of antagonists of calcineurin attenuates the hypertrophic response of neonatal rat ventricular myocytes to stimuli such as phenylephrine (PE) and angiotensin II ([@bib99]).

Apoptotic pathways.
-------------------

Apoptosis has recently been shown to play a major role in cardiac disease ([@bib26]). Adult cardiomyocytes are terminally differentiated, so cell loss is detrimental to cardiac function. Additionally, when cardiomyocytes are lost, deposition of collagen occurs. Ultimately, this decreases heart compliance, increases cardiomyocyte wall stress, and impairs ventricular relaxation.

Apoptosis has been demonstrated in HCM and DCM as evidenced by activated apoptotic pathway components and caspase activity ([@bib71]; [@bib76]; [@bib2]). Many of the signaling pathways activated with increased cardiomyocyte stretch are implicated in regulation of apoptosis, including Akt and adrenergic stimulation. Several groups have demonstrated that hyperactivation of β-adrenergic signaling pathways and cytochrome *c* release from mitochondria are associated with increased apoptosis and fibrosis ([@bib9]; [@bib25]; [@bib38]; [@bib72]). Additionally, evidence for increased signaling through Fas receptors by up-regulation of TNF is common in heart failure, and the degradation of inhibitors of Fas receptor signaling such as cFlip is another mechanism by which apoptosis may occur ([@bib49]; [@bib101]). Studies from human heart biopsies reveal that greater cell loss is observed in the early stages of cardiomyopathy, suggesting that anti-apoptotic pathways are up-regulated after cell loss has been initiated ([@bib2]). It follows that tight regulation of apoptosis is required for proper cardiac adaptation and that disruption of these pathways can have irreversible consequences in the heart.

Summary
=======

Advances in molecular techniques have vastly improved the understanding of mechanisms responsible for cardiac dysfunction in cardiomyopathies. It is clear that mutant proteins in cardiomyocytes can perturb cardiac function whether they occur in the contractile apparatus or in the mechanosensitive complexes. Alterations in cardiomyocyte function initiate cascades of cellular responses that attempt to compensate for these insults by normalizing functional parameters in the cells. However, persistent responses at the cellular level lead to organ-wide alterations that are highly correlated with sudden cardiac death and heart failure. Much remains to be learned about precise mechanisms that modulate the transition between compensatory responses in the heart and the development of heart failure.

Despite these challenges, basic studies of the processes that mediate cellular responses to cardiac stress have allowed the development of therapeutics for some cardiomyopathies that include drugs that decrease blood pressure and heart rate (angiotensin II receptor antagonists, Ca^2+^ channel blockers) to reduce the strain on the ventricular walls. Implantable devices that regulate the synchronization of contraction also reduce the progression of cardiomyopathies ([@bib83]). Although there exist no treatments to directly address the causes of inherited cardiomyopathies, cell transplantation, gene therapy, small interfering RNAs, and microRNAs remain on the horizon of innovative treatments that address the causes rather than reduction of symptoms of cardiomyopathies. Utilization of animal and cellular models to further probe the mechanisms of cardiomyopathy and demonstrate efficacy of drugs that specifically target disease-causing pathways hold promise that further reduction in the mortality associated with cardiomyopathies can be achieved.

We gratefully acknowledge Dr. Massimo Buvoli for useful discussion related to the content of this manuscript and Dr. Kristen Barthel, Dr. Matthew Bell, and Christopher Haines for critical review. We also thank Dr. Brian O'Rourke for providing images used in [Fig. 3, C and D](#fig3){ref-type="fig"}.

This work was supported by National Institutes of Health grant HL-50560 (L.A. Leinwand) and National Institutes of Health training grant T32 HL-07822 (P.A. Harvey).

Abbreviations used in this paper:DCMdilated cardiomyopathyHCMhypertrophic cardiomyopathyMyHCmyosin heavy chainRCMrestrictive cardiomyopathy
